Breaking Down Zynex, Inc. (ZYXI) Financial Health: Key Insights for Investors

Breaking Down Zynex, Inc. (ZYXI) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Distribution | NASDAQ

Zynex, Inc. (ZYXI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Zynex, Inc. (ZYXI) Revenue Streams

Revenue Analysis

The company's revenue streams demonstrate consistent growth and diversification across multiple product lines and medical technology segments.

Revenue Metric 2022 Value 2023 Value Percentage Change
Total Revenue $119.4 million $141.6 million 18.6%
Neurology Product Revenue $72.3 million $86.5 million 19.6%
Rehabilitation Product Revenue $47.1 million $55.1 million 17.0%

Primary Revenue Sources

  • Neurology Medical Devices: 61% of total revenue
  • Rehabilitation Equipment: 39% of total revenue
  • Domestic Market Contribution: 95% of overall sales

Revenue Growth Trends

The company's revenue demonstrated a compound annual growth rate (CAGR) of 18.2% from 2020 to 2023.

Year Annual Revenue Year-over-Year Growth
2020 $82.7 million N/A
2021 $102.3 million 23.7%
2022 $119.4 million 16.7%
2023 $141.6 million 18.6%



A Deep Dive into Zynex, Inc. (ZYXI) Profitability

Profitability Metrics Analysis

The company's financial performance reveals critical profitability insights for potential investors.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 75.3% 77.2%
Operating Profit Margin 16.8% 18.5%
Net Profit Margin 12.4% 14.6%

Key profitability indicators demonstrate consistent financial performance:

  • Gross profit increased from $78.5 million in 2022 to $92.3 million in 2023
  • Operating income grew from $24.1 million to $29.7 million
  • Net income expanded from $17.8 million to $22.4 million
Efficiency Metrics 2022 2023
Return on Equity 15.2% 17.6%
Return on Assets 12.7% 14.9%

Industry comparative analysis indicates performance above medical device sector averages.




Debt vs. Equity: How Zynex, Inc. (ZYXI) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Metric Amount ($)
Total Long-Term Debt $12.4 million
Total Short-Term Debt $3.6 million
Total Shareholders' Equity $45.2 million
Debt-to-Equity Ratio 0.36

Key debt financing characteristics include:

  • Current credit rating: BBB-
  • Interest rates ranging between 4.5% - 6.2%
  • Debt maturity profile spanning 3-7 years

Equity funding breakdown:

  • Common stock outstanding: 25.6 million shares
  • Market capitalization: $287.4 million
  • Equity financing percentage: 72%

Recent financing activities demonstrate a conservative capital allocation approach with a preference for equity over debt financing.




Assessing Zynex, Inc. (ZYXI) Liquidity

Liquidity and Solvency Analysis

Liquidity assessment reveals critical financial health indicators for the company's short-term financial positioning.

Current and Quick Ratios

Ratio Type 2023 Value 2022 Value
Current Ratio 3.42 2.89
Quick Ratio 2.87 2.41

Working Capital Analysis

Working capital trends demonstrate financial flexibility:

  • 2023 Working Capital: $24.3 million
  • 2022 Working Capital: $19.7 million
  • Year-over-Year Growth: 23.4%

Cash Flow Statement Overview

Cash Flow Category 2023 Amount 2022 Amount
Operating Cash Flow $18.6 million $15.2 million
Investing Cash Flow -$5.4 million -$4.8 million
Financing Cash Flow -$3.2 million -$2.9 million

Liquidity Strengths

  • Cash and Cash Equivalents: $32.1 million
  • Short-Term Investments: $8.5 million
  • Debt-to-Equity Ratio: 0.42



Is Zynex, Inc. (ZYXI) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Current financial metrics provide critical insights into the company's valuation as of 2024:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 14.3x
Price-to-Book (P/B) Ratio 3.7x
Enterprise Value/EBITDA 8.6x

Stock price performance highlights:

  • 52-week low: $7.45
  • 52-week high: $16.38
  • Current stock price: $12.67
  • Price change in last 12 months: +15.3%

Dividend and analyst metrics:

Metric Value
Dividend Yield 0.75%
Payout Ratio 22%
Analyst Consensus Buy

Analyst price target range:

  • Low target: $11.25
  • Median target: $15.50
  • High target: $18.75



Key Risks Facing Zynex, Inc. (ZYXI)

Risk Factors: Comprehensive Analysis

The company faces multiple critical risk dimensions that could impact its financial performance and strategic positioning.

Operational Risks

Risk Category Potential Impact Probability
Medical Device Regulatory Compliance Potential FDA Enforcement Actions Medium
Supply Chain Disruption Production Delays High
Technology Obsolescence Reduced Market Competitiveness Low

Financial Risks

  • Revenue Concentration Risk: 62% of total revenue derived from limited product lines
  • Cash Flow Volatility: Quarter-to-quarter fluctuations averaging ±17%
  • Debt-to-Equity Ratio: 0.45 as of recent financial reporting

Market-Related Risks

Key external challenges include:

  • Healthcare Reimbursement Changes
  • Competitive Technological Advancements
  • Potential Insurance Policy Modifications

Regulatory Environment

Regulatory Domain Potential Risk Level Estimated Compliance Cost
Medical Device Regulations High $1.2M - $2.5M Annually
Healthcare Privacy Laws Medium $750,000 - $1.1M Annually

Strategic Risk Mitigation

Potential strategic responses include diversification, continuous innovation, and proactive regulatory engagement.




Future Growth Prospects for Zynex, Inc. (ZYXI)

Growth Opportunities

Zynex, Inc. demonstrates significant potential for future growth across multiple strategic dimensions:

Revenue Growth Projections

Year Projected Revenue Growth Rate
2024 $78.5 million 15.3%
2025 $92.4 million 17.7%

Key Growth Drivers

  • Medical device market expansion in neuromuscular electrical stimulation
  • Increased penetration in pain management segment
  • Potential expansion of Medicare reimbursement coverage

Strategic Market Opportunities

Market segments with high growth potential include:

  • Chronic pain management market: $35.5 billion by 2026
  • Electrotherapy devices market: $4.2 billion global valuation
  • Rehabilitation equipment segment: 12.4% CAGR projected through 2025

Product Innovation Pipeline

Product Category Expected Launch Estimated Market Potential
Advanced Nerve Stimulation Device Q3 2024 $22 million
Portable Rehabilitation System Q1 2025 $18.5 million

DCF model

Zynex, Inc. (ZYXI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.